Oxford Biomedica PLC Total Voting Rights (6991I)

TIDMOXB

RNS Number : 6991I

Oxford Biomedica PLC

01 September 2016

Oxford BioMedica

Total Voting Rights

Oxford, UK - 1 September 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces that in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Group's issued share capital as at the close of business on 31 August 2016 consisted of 2,703,806,022 ordinary shares of 1 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

Accordingly, the total number of voting rights in Oxford BioMedica plc at the date of this notice is 2,703,806,022.

The above figure (2,703,806,022) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford BioMedica plc under the FCA's Disclosure and Transparency Rules.

-Ends-

 
 For further information, 
  please contact: 
  Oxford BioMedica plc:                     Tel: [phone] 
   John Dawson, Chief Executive              783 000 
   Officer 
   Tim Watts, Chief Financial 
   Officer 
  Financial and corporate communications    Tel: [phone] 
   enquiries:                                5700 
   Consilium Strategic Communications 
   Mary-Jane Elliott/Matthew 
   Neal/Chris Welsh/Laura Thornton 
 

Notes for editors

About Oxford BioMedica(R)

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 230 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVREANNFELSKEEF

(END) Dow Jones Newswires

September 01, 2016 05:47 ET (09:47 GMT)